Relay Therapeutics (RLAY) Other Operating Expenses (2021 - 2024)

Relay Therapeutics (RLAY) has reported Other Operating Expenses for 4 consecutive years, with -$11.4 million the latest figure, recorded in Q2 2024.

• In Q2 2024, Other Operating Expenses fell 428.53% year-over-year to -$11.4 million; the TTM figure through Mar 2025 stood at -$11.4 million (down 56.86% YoY), while the FY2024 annual figure was -$13.2 million, down 105.64% from the prior year.
• Other Operating Expenses slipped to -$11.4 million in Q2 2024 per RLAY's latest filing, from -$1.8 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $134.9 million in Q2 2021 and bottomed at -$11.4 million in Q2 2024.
• Historically, Other Operating Expenses has averaged $8.2 million across 4 years, with a median of -$1.2 million in 2023.
• Annual changes were most pronounced in 2022 — Other Operating Expenses tumbled 1361.24% — and 2023, when it jumped 80.4%.
• Relay Therapeutics' Other Operating Expenses stood at $836000.0 in 2021, then sank by 1361.24% to -$10.5 million in 2022, then surged by 80.4% to -$2.1 million in 2023, then tumbled by 450.27% to -$11.4 million in 2024.
• Business Quant data shows RLAY's Other Operating Expenses at -$11.4 million in Q2 2024, -$1.8 million in Q1 2024, and -$2.1 million in Q4 2023.